Serum MicroRNA-122 as A Prognostic Biomarker in Patients with Liver Cirrhosis

  • Jehan Hassan Sabry Assisstant professur of Clinical and Chemical Pathology department , faculty of medicine, Benha University, Egypt
  • Osama Saad El-Shaer Prof. of Clinical & Chemical Pathology ,Benha Faculty of Medicine,Egypt
  • Inas Abd El Mneam Ahmed Lecturer of Medical Biochemistry & Molecular Biology, Benha Faculty of Medicine,Egypt.
  • Ebada Mohamed Said Assist.Professor Gastroenterology & Infectious Diseases Department Benha Faculty of Medicine
  • Amr Mohamed El Hammady Benha Faculty of Medicine
  • Abdelmoneam Ahmed Abdelmoneam Benha Faculty of Medicine
  • Asmaa Adel EL- Fallah Benha Faculty of Medicine
Keywords: Micro RNA 122, MELD score, liver cirrhosis, qPCR, overall survival


Background: Liver cirrhosis is associated with high morbidity and mortality. MicroRNAs (miRNAs), a class of endogenous small non-coding RNAs, are becoming increasingly recognized as crucial regulators in gene expression networks. In particular, a low serum miRNA-122 level was associated with hepatic decompensation so it can be used as a prognostic marker  for liver decompensation.Aim of work : Circulating miRNA-12 was examined aiming to clarify its prongnostic value in patients with liver cirrhosis and to discover  its relation with patient's survival.Methods: Gene expression level of miRNA 122 was extracted and assessed in sera of 100  patients with liver cirrhosis,  using quantitative reverse-transcription PCR (qRT-PCR) . MiRNA 122 expression levels were comparedto liver function tests, MELD score, overall survival time and to different manifestation of decompensation.Results: Serum samples from patients with hepatic decompensation showed significant downregulation of miRNA122compared to those from patients with compensated liver cirrhosis. Patients with ascites, and hepatorenal syndrome had significantly lower miRNA-122 levels than patients without these complications.A univariateCox regression analysis revealed a significantassociation between miRNA-122 levels and overall survival Multivariate Cox regression analysis revealed that only miRNA-122 serum levels and platelet count wereindependent factor for survival. MiRNA-122 sensitivity and specificity for the predection of decompensation in cirrhotic patients were 100.0% and 90.1% respectively the best cut off point value of 0.892 (AUC= 0.9429)Conclusions: Serum miRNA-122 is a useful new independent prognostic marker in patients with liver cirrhosis..

Author Biographies

Amr Mohamed El Hammady, Benha Faculty of Medicine
Lecturer of Internal Medicine Department
Abdelmoneam Ahmed Abdelmoneam, Benha Faculty of Medicine
Lecturer of Internal Medicine Department


1-Schuppan D and Afdhal NH:Liver cirrhosis. Lancet.2008,371: 838–851.
2-Ca´rdenas A and Gine`s P: Management of patients with cirrhosis awaiting liver transplantation. Gut.2011, 60: 412–421.
3-Garcia-Tsao G and Bosch J: Management of varices and varicealhemorrhagein cirrhosis. N Engl J Med.2010, 362: 823–832.
4- Wiesner RH: Patient selection in an era of donor liver shortage: CurrentUS policy. Nat ClinPractGastroenterolHepatol, 2005; 2: 24–30.
5-Chen H, Bai M, Qi X, Liu L, He C, Yin Z, et al.: Child-Na Score: A Predictive Model for Survival in Cirrhotic Patients with Symptomatic Portal Hypertension Treated with TIPS. PLoS ONE. 2013, 8(11): e79637.

6-Etheridge A, Lee I, Hood L, Galas D, Wang K.: Extracellular microRNA: A new source of biomarkers: Mutation Research.2011,717(1): 85-90.
7-Esquela-Kerscher A and Slack FJ :Oncomirs – microRNAs with a role incancer. Nat Rev Cancer.2006, 6: 259–269.
8-Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004; 116: 281-297.
9- Dykxhoorn DM and Lieberman J :The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu. Rev. Med. 2005, 56: 401-423
10- Lewis AP and JoplingCL :Regulation and biological function of the liver-specific miR-122. Biochem. Soc. Trans. 2010, 38: 1553-1557.
11-Boutz DR, Collins PJ, Suresh U,Lu M, Ramírez CM, Fernández-Hernando C, et al., : Two-tieredapproach identifies a network of cancer and liver disease-related genes regulatedby miR-122. J BiolChem. 2011, 286: 18066–18078.
12. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS.: Loss of miR-122 expression in liver cancer correlates with suppression of thehepatic phenotype and gain of metastatic properties. Oncogene.2009, 28: 3526–3536.
13- Scisciani C, Vossio S, GuerrieriF,Schinzari V , De Iaco R , D'Onorio de Meo P, et al.,: Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol.2012, 56: 855-861.

14- Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J, et al., : MiR-122 regulates collagen production via targeting hepaticstellate cells and suppressing P4HA1 expression. J Hepatol.2013,58: 522-528.
15- Arroyo V, Ginès P, Gerbes AL, et al. : Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.Hepatology. 1996,23 (1): 164–176.

16- Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DeltaDelta C(T))Method. Methods. 2001, 25, 402.

17- Sørensen HT, Thulstrup AM, Mellemkjar L, et al., Longterm survival and cause-specific mortality in patients with cirrhosis of the liver: a nationwide cohort study in Denmark. Journal of Clinical Epidemiology. 2003, 56(1): 88–93.

18- Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, et al. :Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J. Hepatol. 2013, 58:234-239.

19- Wang K, Zhang S, Weber J, Baxter D, Galas DJ.: Export of microRNAs and microRNA-protective protein by mammalian cells. Nucl Acids Res. 2010, 38: 7248–7259.

20- Halász T, Horváth G, Pár G, et al., MiR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan. World J Gastroenterol, 2015; 21(25): 7814-7823.
21- Hu J, Xu Y, Hao J, Wang S, Li C, Meng S.: MiR-122 in hepatic function and liver diseases. Protein Cell. 2012, 3: 364-371
22- Waidmann O, Kberle V, Brunner F,Zeuzem S, Piiper A, Kronenberger B. : Serum MicroRNA-122 Predicts Survival in Patients with Liver Cirrhosis PLoS ONE, 2012, 7(9): e45652.

23- Ko¨berle V, Kronenberger B, Pleli T, et al.,: Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. European Journal of Cancer. 2013, 49(16): 3442-3449.

24- Kholeif H, MohamedAboulEla A, Badawy D : Circulating Micro RNA-122 in Hepatitis C Virus Infected in Egyptian Group of Patients Clinical Medicine and Diagnostics. 2015, 5(6): 114-121.
25- Starkey PJ, Dear J, Platt V, et al., :Circulating microRNAs as potential markers of human drug induced liver injury. Hepatology.2011, 5: 1767–1776.
26- AbdElmouttaleb AT, Abd-Elatif DM, Soliman GM, Taher MS, Abonar AA. : Serum Micro RNA-122 as a Biomarker for Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients. Research In Cancer and Tumor. 2015, 4(2): 25-33.
27- Ding X, Ding J, Ning J,Yi F, Chen J, Zhao D, et al., : Circulating microRNA-122 as a potential biomarker for liver injury. Mol Med Rep. 2012, 5(6):1428-1432.

28-Jung CJ, Iyengar S, Blahnik KR, et al., : Epigenetic modulation of miR-122 facilitates human embryonic stem cell selfrenewal and hepatocellular carcinoma proliferation. PLoS One. 2011,6(11):e27740.
29-Bihrer V, Friedrich-Rust M, Kronenberger B, et al., : Serum miR- 122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol, 2011, 106: 1663–1669.
30- Cermelli S, Ruggieri A, Marrero JA, Ioannou G, Beretta L.: Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011, 6:e23937.

31-Botta F, Giannini E, Romagnoli P, et al., MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut. 2003, 52(1): 134–139.

32- Bureau C, Métivier S, D’Amico M, et al., Serum bilirubin and platelet count: A simple predictive model for survival in patients with refractory ascites treated by TIPS. Journal of Hepatology.2011,54: 901–907.
33- Afdhal N, McHutchison J, Brown R, et al., :Thrombocytopenia associated with chronic liver disease. Journal of Hepatology. 2008, 48: 1000–1007.
Original Article